Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgical Mesh | 19 | 2018 | 50 | 5.460 |
Why?
|
| Urinary Incontinence, Stress | 20 | 2019 | 75 | 5.170 |
Why?
|
| Pelvic Organ Prolapse | 14 | 2020 | 48 | 3.910 |
Why?
|
| Prostatic Hyperplasia | 17 | 2020 | 59 | 2.620 |
Why?
|
| Urinary Bladder, Overactive | 7 | 2020 | 63 | 2.240 |
Why?
|
| Uterine Prolapse | 7 | 2018 | 21 | 1.930 |
Why?
|
| Urinary Incontinence | 6 | 2018 | 68 | 1.900 |
Why?
|
| Suburethral Slings | 6 | 2020 | 14 | 1.890 |
Why?
|
| Urethra | 6 | 2019 | 125 | 1.560 |
Why?
|
| Ablation Techniques | 9 | 2020 | 25 | 1.330 |
Why?
|
| Urodynamics | 8 | 2020 | 88 | 1.270 |
Why?
|
| Biocompatible Materials | 6 | 2014 | 242 | 1.270 |
Why?
|
| Pelvic Floor | 7 | 2017 | 23 | 1.230 |
Why?
|
| Urology | 3 | 2014 | 33 | 1.220 |
Why?
|
| Humans | 74 | 2020 | 34474 | 1.080 |
Why?
|
| Prostatectomy | 7 | 2020 | 85 | 1.080 |
Why?
|
| Prostate | 8 | 2020 | 89 | 1.070 |
Why?
|
| Urologic Diseases | 4 | 2014 | 35 | 1.020 |
Why?
|
| Vagina | 6 | 2020 | 61 | 1.010 |
Why?
|
| Urologic Surgical Procedures | 6 | 2018 | 66 | 0.920 |
Why?
|
| Regenerative Medicine | 3 | 2019 | 219 | 0.860 |
Why?
|
| Prostheses and Implants | 4 | 2018 | 53 | 0.850 |
Why?
|
| Prosthesis Failure | 2 | 2015 | 58 | 0.820 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 364 | 0.810 |
Why?
|
| Female | 42 | 2020 | 21490 | 0.810 |
Why?
|
| Cystitis, Interstitial | 6 | 2020 | 58 | 0.780 |
Why?
|
| Urinary Catheterization | 3 | 2020 | 23 | 0.760 |
Why?
|
| Transurethral Resection of Prostate | 6 | 2020 | 8 | 0.760 |
Why?
|
| Stents | 4 | 2015 | 167 | 0.740 |
Why?
|
| Algorithms | 4 | 2018 | 560 | 0.740 |
Why?
|
| Polypropylenes | 3 | 2012 | 7 | 0.670 |
Why?
|
| Postoperative Complications | 9 | 2020 | 849 | 0.660 |
Why?
|
| Internship and Residency | 3 | 2014 | 330 | 0.640 |
Why?
|
| Tissue Engineering | 2 | 2019 | 700 | 0.630 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2020 | 50 | 0.620 |
Why?
|
| Urinary Bladder Diseases | 3 | 2020 | 45 | 0.620 |
Why?
|
| Reconstructive Surgical Procedures | 4 | 2020 | 202 | 0.600 |
Why?
|
| Urinary Bladder Neck Obstruction | 2 | 2017 | 30 | 0.580 |
Why?
|
| Urinary Bladder | 7 | 2019 | 320 | 0.580 |
Why?
|
| Hydronephrosis | 1 | 2017 | 12 | 0.550 |
Why?
|
| Ureteral Diseases | 1 | 2017 | 8 | 0.550 |
Why?
|
| Treatment Outcome | 17 | 2020 | 3618 | 0.520 |
Why?
|
| Prosthesis Design | 2 | 2015 | 116 | 0.510 |
Why?
|
| Water | 8 | 2020 | 70 | 0.510 |
Why?
|
| Aged | 28 | 2020 | 10998 | 0.470 |
Why?
|
| Urethral Obstruction | 1 | 2015 | 12 | 0.460 |
Why?
|
| Exercise Therapy | 2 | 2018 | 283 | 0.460 |
Why?
|
| Medical Device Recalls | 1 | 2015 | 2 | 0.450 |
Why?
|
| Public Opinion | 1 | 2014 | 17 | 0.430 |
Why?
|
| Male | 29 | 2020 | 20697 | 0.420 |
Why?
|
| Device Removal | 2 | 2012 | 44 | 0.420 |
Why?
|
| Compensation and Redress | 1 | 2013 | 4 | 0.410 |
Why?
|
| Malpractice | 1 | 2013 | 22 | 0.410 |
Why?
|
| Liability, Legal | 1 | 2013 | 25 | 0.410 |
Why?
|
| Quality of Life | 6 | 2019 | 1032 | 0.400 |
Why?
|
| Muscle Contraction | 2 | 2018 | 183 | 0.390 |
Why?
|
| Myoblasts | 3 | 2017 | 42 | 0.370 |
Why?
|
| Tissue Transplantation | 1 | 2012 | 17 | 0.360 |
Why?
|
| Prosthesis Implantation | 2 | 2015 | 41 | 0.340 |
Why?
|
| Collagen | 4 | 2017 | 239 | 0.340 |
Why?
|
| Middle Aged | 24 | 2020 | 12703 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2014 | 565 | 0.310 |
Why?
|
| Retrospective Studies | 12 | 2020 | 3812 | 0.300 |
Why?
|
| Animals | 12 | 2019 | 8544 | 0.300 |
Why?
|
| Muscarinic Antagonists | 1 | 2009 | 41 | 0.290 |
Why?
|
| Physical Therapy Modalities | 2 | 2019 | 84 | 0.280 |
Why?
|
| Dietary Proteins | 1 | 2008 | 66 | 0.280 |
Why?
|
| Soybean Proteins | 1 | 2008 | 102 | 0.270 |
Why?
|
| Postoperative Hemorrhage | 2 | 2018 | 41 | 0.270 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 4150 | 0.260 |
Why?
|
| Urethral Diseases | 2 | 2018 | 20 | 0.260 |
Why?
|
| Stroke | 1 | 2012 | 700 | 0.250 |
Why?
|
| Microwaves | 2 | 2008 | 9 | 0.230 |
Why?
|
| Pelvic Pain | 2 | 2017 | 23 | 0.230 |
Why?
|
| Recovery of Function | 2 | 2020 | 251 | 0.220 |
Why?
|
| Forecasting | 2 | 2018 | 153 | 0.220 |
Why?
|
| Follow-Up Studies | 5 | 2015 | 2366 | 0.220 |
Why?
|
| Prevalence | 3 | 2017 | 1034 | 0.220 |
Why?
|
| Diathermy | 1 | 2004 | 1 | 0.220 |
Why?
|
| Time Factors | 8 | 2020 | 2352 | 0.210 |
Why?
|
| Organ Size | 6 | 2020 | 236 | 0.210 |
Why?
|
| Prostatic Neoplasms | 3 | 2018 | 498 | 0.200 |
Why?
|
| Peptides | 1 | 2004 | 142 | 0.190 |
Why?
|
| Adult | 9 | 2020 | 10015 | 0.190 |
Why?
|
| Syndrome | 2 | 2020 | 76 | 0.190 |
Why?
|
| Urethral Stricture | 2 | 2017 | 31 | 0.180 |
Why?
|
| Prospective Studies | 8 | 2020 | 2461 | 0.180 |
Why?
|
| Risk Assessment | 2 | 2017 | 1506 | 0.170 |
Why?
|
| Erectile Dysfunction | 2 | 2018 | 71 | 0.160 |
Why?
|
| Endoscopy | 2 | 2019 | 56 | 0.160 |
Why?
|
| Urinary Retention | 1 | 2020 | 10 | 0.160 |
Why?
|
| Incidence | 2 | 2014 | 1288 | 0.160 |
Why?
|
| Chemokine CXCL12 | 2 | 2018 | 29 | 0.160 |
Why?
|
| Hospitals | 1 | 2020 | 105 | 0.150 |
Why?
|
| Polyneuropathies | 1 | 2019 | 11 | 0.150 |
Why?
|
| Hydrotherapy | 1 | 2019 | 4 | 0.150 |
Why?
|
| Endometriosis | 1 | 2020 | 103 | 0.150 |
Why?
|
| Macaca fascicularis | 4 | 2018 | 548 | 0.150 |
Why?
|
| Fibromyalgia | 1 | 2019 | 26 | 0.150 |
Why?
|
| Anesthesia | 1 | 2019 | 72 | 0.140 |
Why?
|
| Hernia, Inguinal | 1 | 2018 | 4 | 0.140 |
Why?
|
| Pubic Symphysis Diastasis | 1 | 2018 | 3 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2010 | 70 | 0.140 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2018 | 11 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2018 | 33 | 0.140 |
Why?
|
| Electric Stimulation Therapy | 1 | 2018 | 19 | 0.140 |
Why?
|
| Patient Positioning | 1 | 2018 | 23 | 0.140 |
Why?
|
| Aging | 3 | 2017 | 1010 | 0.140 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2018 | 30 | 0.140 |
Why?
|
| Electrocoagulation | 1 | 2018 | 12 | 0.140 |
Why?
|
| Adenoma | 1 | 2018 | 36 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2018 | 104 | 0.140 |
Why?
|
| Risk Factors | 5 | 2020 | 4136 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2017 | 74 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 47 | 0.130 |
Why?
|
| Double-Blind Method | 4 | 2020 | 597 | 0.130 |
Why?
|
| Elastin | 2 | 2014 | 17 | 0.130 |
Why?
|
| Behavior Therapy | 1 | 2018 | 107 | 0.130 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 47 | 0.130 |
Why?
|
| RNA | 2 | 2016 | 99 | 0.130 |
Why?
|
| Patient Satisfaction | 2 | 2010 | 245 | 0.130 |
Why?
|
| Self Care | 1 | 2018 | 144 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 230 | 0.130 |
Why?
|
| Control Groups | 1 | 2016 | 5 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2017 | 378 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 100 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 540 | 0.120 |
Why?
|
| Education, Medical, Graduate | 2 | 2014 | 138 | 0.110 |
Why?
|
| Gene Expression | 1 | 2016 | 362 | 0.110 |
Why?
|
| Frail Elderly | 1 | 2015 | 73 | 0.110 |
Why?
|
| Laser Therapy | 1 | 2015 | 56 | 0.110 |
Why?
|
| United States | 2 | 2014 | 4267 | 0.110 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 922 | 0.110 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 1118 | 0.100 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 56 | 0.100 |
Why?
|
| Cystocele | 2 | 2017 | 4 | 0.100 |
Why?
|
| Internet | 1 | 2014 | 207 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 48 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2014 | 186 | 0.090 |
Why?
|
| Extracellular Matrix | 2 | 2011 | 260 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 526 | 0.090 |
Why?
|
| Cadaver | 2 | 2016 | 169 | 0.090 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2010 | 45 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 20 | 0.080 |
Why?
|
| Regeneration | 1 | 2011 | 179 | 0.080 |
Why?
|
| Credentialing | 1 | 2009 | 9 | 0.080 |
Why?
|
| Benzofurans | 1 | 2009 | 5 | 0.080 |
Why?
|
| Pyrrolidines | 1 | 2009 | 16 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 228 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 113 | 0.070 |
Why?
|
| Cystectomy | 1 | 2010 | 110 | 0.070 |
Why?
|
| Carbachol | 1 | 2008 | 17 | 0.070 |
Why?
|
| BCG Vaccine | 1 | 2008 | 9 | 0.070 |
Why?
|
| Phenylephrine | 1 | 2008 | 35 | 0.070 |
Why?
|
| Tissue Culture Techniques | 1 | 2008 | 44 | 0.070 |
Why?
|
| Probability | 1 | 2008 | 168 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 63 | 0.070 |
Why?
|
| Patient Selection | 1 | 2010 | 291 | 0.070 |
Why?
|
| Hematuria | 1 | 2008 | 11 | 0.070 |
Why?
|
| Reference Values | 1 | 2008 | 265 | 0.070 |
Why?
|
| Tissue Scaffolds | 1 | 2011 | 435 | 0.070 |
Why?
|
| Random Allocation | 1 | 2008 | 257 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2008 | 204 | 0.070 |
Why?
|
| Robotics | 1 | 2009 | 135 | 0.070 |
Why?
|
| Biological Products | 1 | 2009 | 80 | 0.070 |
Why?
|
| Muscle, Smooth | 1 | 2008 | 152 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2010 | 196 | 0.060 |
Why?
|
| Embolization, Therapeutic | 1 | 2008 | 86 | 0.060 |
Why?
|
| Pyelonephritis, Xanthogranulomatous | 1 | 2007 | 2 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 612 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 593 | 0.060 |
Why?
|
| Suture Techniques | 1 | 2007 | 61 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2018 | 323 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 1078 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 205 | 0.060 |
Why?
|
| Primates | 2 | 2017 | 130 | 0.060 |
Why?
|
| Prolapse | 1 | 2005 | 5 | 0.060 |
Why?
|
| Fascia | 1 | 2005 | 10 | 0.060 |
Why?
|
| Phenotype | 2 | 2020 | 656 | 0.060 |
Why?
|
| Nephrectomy | 1 | 2007 | 127 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 317 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2007 | 194 | 0.050 |
Why?
|
| Collagen Type III | 1 | 2004 | 9 | 0.050 |
Why?
|
| Pyridinium Compounds | 1 | 2004 | 4 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 325 | 0.050 |
Why?
|
| Cross-Linking Reagents | 1 | 2004 | 17 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2004 | 48 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2016 | 438 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 165 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2016 | 583 | 0.050 |
Why?
|
| Pelvis | 2 | 2018 | 68 | 0.050 |
Why?
|
| Adolescent | 3 | 2019 | 3799 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2004 | 429 | 0.040 |
Why?
|
| Young Adult | 2 | 2019 | 2825 | 0.040 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 46 | 0.040 |
Why?
|
| Anesthetics | 1 | 2019 | 21 | 0.040 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2018 | 4 | 0.040 |
Why?
|
| Sexual Behavior, Animal | 1 | 2018 | 11 | 0.040 |
Why?
|
| Perineum | 1 | 2018 | 18 | 0.040 |
Why?
|
| Prostatism | 1 | 2018 | 4 | 0.040 |
Why?
|
| Hemostasis, Surgical | 1 | 2018 | 12 | 0.040 |
Why?
|
| Ejaculation | 1 | 2018 | 7 | 0.030 |
Why?
|
| Endosonography | 1 | 2018 | 55 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2018 | 22 | 0.030 |
Why?
|
| Hernia | 1 | 2017 | 11 | 0.030 |
Why?
|
| Compliance | 1 | 2017 | 14 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 335 | 0.030 |
Why?
|
| Pressure | 1 | 2017 | 70 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 101 | 0.030 |
Why?
|
| Chemokines | 1 | 2016 | 36 | 0.030 |
Why?
|
| Social Behavior | 1 | 2017 | 74 | 0.030 |
Why?
|
| Urine | 1 | 2017 | 70 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 197 | 0.030 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2016 | 115 | 0.030 |
Why?
|
| Color | 1 | 2015 | 13 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2015 | 63 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 55 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2015 | 76 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 343 | 0.030 |
Why?
|
| Sweden | 1 | 2014 | 17 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 21 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2014 | 28 | 0.030 |
Why?
|
| Biopsy | 1 | 2014 | 268 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1386 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2011 | 11 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2009 | 58 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 849 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 214 | 0.020 |
Why?
|
| Urination | 1 | 2008 | 69 | 0.020 |
Why?
|
| Arteries | 1 | 2008 | 83 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2007 | 80 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2009 | 349 | 0.020 |
Why?
|
| Subcutaneous Tissue | 1 | 2004 | 6 | 0.010 |
Why?
|
| Abdomen | 1 | 2004 | 52 | 0.010 |
Why?
|
| Urethral Neoplasms | 1 | 2003 | 5 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 120 | 0.010 |
Why?
|
| Metaplasia | 1 | 2003 | 19 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2003 | 29 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 295 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 192 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 222 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 984 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 887 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 924 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2003 | 168 | 0.010 |
Why?
|